Red Arrow Therapeutics

Red Arrow Therapeutics, Inc.

is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, with a research facility in Tokyo. Founded in August 2021, the company focuses on developing pH-sensing nanopolymer drug-delivery systems aimed at enhancing cancer therapies. Their proprietary technology utilizes biocompatible, pH-sensitive nanopolymers that self-assemble into micelles, which protect sensitive therapeutics until they reach targeted disease sites, such as tumors. The company's lead product candidate, RA-001, is designed to release Interleukin-12 (IL-12) in response to the acidic environment of tumors, promoting effective immunotherapy while minimizing damage to healthy tissue. Red Arrow Therapeutics aims to address the needs of cancer patients with solid tumors and other difficult-to-treat diseases, seeking to replace traditional chemotherapy with safer immunotherapies. The company is also planning to expand its pipeline to include Antibody-Drug Conjugates, T-cell engagers, and gene editing technologies.